コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 orpholinone and the piperidinone series will be described herein.
2 (MBE) on c-plane sapphire and GaN templates is described herein.
3 ylates to unusual chiral cyclic sulfoximines is described herein.
4 a-nitrogenated aldehydes in very good yields is described herein.
5 mma-keto allyl phosphonates in 70-93% yields is described herein.
6 of phosphorothioate and native DNA sequences is described herein.
7 hen]-3(2H)-one (DEMAX) for Al(III) chelation is described herein.
8 e, mild bromination of thieno[2,3-b]pyridine is described herein.
9 titanocene-catalyzed multicomponent coupling is described herein.
10 A novel PCR assay is described herein.
11 tal characterization of a DC-only ion funnel is described herein.
12 opy of a Neisseria gonorrhoeae 16S rRNA gene is described herein.
13 azinanones, precursors to verdazyl radicals, is described herein.
14 ontaining polycyclic conjugated hydrocarbons is described herein.
15 relatively nonstabilized carbon nucleophiles is described herein.
16 kaloid and potential biosynthetic precursor, is described herein.
17 ally hindered proazaphosphatrane shown above is described herein.
18 pha-chloro and alpha-fluoro carboxylic acids is described herein.
19 e self-assembly and subsequent hydrogelation is described herein.
20 egy of delivering hydrogen persulfide (H2S2) is described herein.
21 of a class of indole cPLA 2 alpha inhibitors is described herein.
22 An X-ray crystal structure of this complex is described herein.
23 determined to actually have a chylous cyst, is described herein.
24 The SAR study leading to the discovery of 6b is described herein.
25 accharides to polypeptides and even proteins is described herein.
26 okinetic profile of this series of compounds is described herein.
27 mide) dendrimers up to the second generation is described herein.
28 ent four-step synthetic route for compound 1 is described herein.
29 y of different imaging or therapeutic agents is described herein.
30 ed tetracyclic core of phomoidrides B and D, is described herein.
31 synthesis of several quinone sesquiterpenes is described herein.
32 the scope and limitations of such reactions is described herein.
33 ytic asymmetric alpha-amination of aldehydes is described herein.
34 netically engineered enzyme-ligand conjugate is described herein.
35 2, utilizing a palladium-catalyzed coupling, is described herein.
36 Lewis acid ionophore [9]mercuracarborand-3, is described herein.
37 the identification of the clinical candidate are described herein.
38 s and challenges of each of these approaches are described herein.
39 f the clinical candidate, JNJ-42847922 (34), are described herein.
40 the last few years by the two new strategies are described herein.
41 interactions observed with the MDM2 protein are described herein.
42 iples derived from these theoretical studies are described herein.
43 nship studies that led to the discovery of 1 are described herein.
44 g protocols to test for these common alleles are described herein.
45 The design, synthesis, and evaluation of 2 are described herein.
46 dipity has played in the collaborations that are described herein.
47 rt, NaClO(3) crystals dyed with aniline blue are described herein.
48 ation of potent and selective PKD inhibitors are described herein.
49 n and synthesis of highly clustered antigens are described herein.
50 vivo properties of representative compounds are described herein.
51 The synthesis and reactivity of 1 are described herein.
52 of preliminary immunological investigations are described herein.
53 ing; advances in those applications and more are described herein.
54 The details of the synthesis are described herein.
55 ity of two thieno-separated purine analogues are described herein.
56 nnojirimycin and (+)-1-deoxyallonojirimycin, are described herein.
57 that of protein enzymes and larger ribozymes are described herein.
58 of unmodified DNA of any length or sequence are described herein.
59 of an ester group followed by lactonization are described herein.
60 long with evidence of implementation success are described herein.
61 athways activated by these injurious stimuli are described herein and will serve as a basis for futur
62 accharides with distinct structural patterns is described herein, and the influence of the targeted s
63 phosphothionate (PT) analogues of PtdIns(5)P is described herein, and the resulting metabolically sta
64 e potent, selective 5-HT2C receptor agonists is described herein as we continue our efforts to optimi
66 dary aliphatic or aromatic and heterocyclic, is described herein by the reaction of easily prepared o
67 synthesis of these marine sponge metabolites is described herein, featuring an oxidative rearrangemen
68 f vitamin D using affinity based biosensors, are described herein; firstly, an immunosensor based on
70 ubsp. pruinosa (Vogel) Fortunato & Wunderlin is described herein for the first time, accounting for e
71 ics of Critical Illness and Injury Symposium are described herein, in addition to deliverables for th
72 f saturated nitrogen-containing heterocycles is described herein, involving the implementation of rut
73 graphene directly from a graphite electrode is described herein obviating the need for defect induci
75 ations in the Drosophila Rap1 and Ras1 genes are described herein that interact genetically with fat
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。